Mr. Mayes is the Chief Executive Officer and a board member of Antios Therapeutics. Prior to Antios and drawing on inspiration from his son’s epilepsy diagnosis, he raised $40 million from prominent investors and founded the clinical-stage pharmaceutical company, Engage Therapeutics, to develop a product candidate for seizures. Upon approval, Staccato® Alprazolam will be the first and only drug-device-combination for the rapid termination of an active epileptic seizure. Engage was sold to UCB in 2020 in a deal valued at $270 million following the successful completion of its randomized, phase 2b clinical study. Prior to Engage, Mr. Mayes played an integral role in the growth of Advaxis Immunotherapies (NASDAQ: ADXS), a biotech company developing immuno-oncology therapies for patients with hard-to-treat cancers through its bacterial vector system, Lm Technology™. As its Chief Operating Officer, he was instrumental in helping to secure in excess of $200 million in follow-on funding and developing partnerships with companies such as Amgen, AstraZeneca and Merck & Co. From 2004 to 2010, Mr. Mayes served as Vice President, General Counsel, and Chief Compliance Officer at ImClone Systems Corporation. During his tenure at ImClone, Mr. Mayes supported the clinical development and commercialization of ERBITUX® and contributed significantly to activities that resulted in its acquisition by Eli Lilly for $6.5 billion in 2008. Mr. Mayes is a cum laude graduate of Syracuse University where he was recognized as a Remembrance Scholar and he earned his J.D. degree magna cum laude from the Temple University School of Law where he was the Articles Editor on the Temple Law Review.
Anthony B. Evnin, Ph.D. has been a Partner at Venrock, a venture capital firm, since 1975. Dr. Evnin currently serves on the Board of Directors of AVEO Pharmaceuticals and Infinity Pharmaceuticals as well as on the Boards of two private companies, Constellation Pharmaceuticals and Juno Therapeutics. He is a Trustee of The Rockefeller University, a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center, a Trustee of The Jackson Laboratory, a Director of the New York Genome Center, a Member of the Board of Directors of the Albert and Mary Lasker Foundation, and a Trustee Emeritus of Princeton University. Dr. Evnin received an A.B. in chemistry from Princeton University and a Ph.D. in chemistry from the Massachusetts Institute of Technology.
Kenneth M. Bate has served as a director since December 2007. He is currently an independent biotech industry consultant. Mr. Bate previously served as President and Chief Executive Officer of Archemix, Inc. from May 2009 to January 2012. From 2006 to 2009, Mr. Bate served in various positions at Nitromed, Inc., most recently as President and Chief Executive Officer. From 2002 to 2005, Mr. Bate served as Chief Financial Officer and head of commercial operations of Millennium Pharmaceuticals Inc. Mr. Bate served as the Chairman of the Board of Cubist Pharmaceuticals, Inc. from 2011 to 2015. In addition to serving on the Board of Directors of AVEO, Mr. Bate serves on the Board of Genocea Biosciences, Inc., Catabasis Pharmaceuticals, Inc. Epizyme, Inc. and TransMedics, Inc. Mr. Bate received his B.A. in Chemistry from Williams College and his M.B.A. from the Wharton School of the University of Pennsylvania.